CYTOKINETICS INC (CYTK:NASDAQ)
$62.99 -0.32 (-0.5054%)
Analysed CYTOKINETICS INC (CYTK:NASDAQ) News Sources
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
12-10-2026
yahoo.com
Cytokinetics (CYTK) Reports Phase 3 Aficamten Gains In Non Obstructive HCM
13-10-2026
yahoo.com
Cytokinetics (CYTK) Stock Looks Hard To Pin Down Following Strong Heart Drug Updates
13-10-2026
yahoo.com
Cytokinetics (CYTK), What Is Behind The Fresh Attention?
13-10-2026
yahoo.com
Aficamten’s ACACIA-HCM Multi-Domain Gains Might Change The Case For Investing In Cytokinetics (CYTK)
13-10-2026
yahoo.com
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
19-10-2026
yahoo.com
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
19-10-2026
yahoo.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19-10-2026
yahoo.com
Cytokinetics to Announce Third Quarter Results on November 4, 2026
21-10-2026
yahoo.com
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?
28-10-2026
yahoo.com
What is the current price of CYTOKINETICS INC (CYTK:NASDAQ)?
The current price of CYTOKINETICS INC (CYTK:NASDAQ) is $62.99.
CYTOKINETICS INC (CYTK:NASDAQ) absolute price change since previous trading day?
The absolute price change of CYTOKINETICS INC (CYTK:NASDAQ) since the previous trading day is $-0.32.
CYTOKINETICS INC (CYTK:NASDAQ) percentage price change since previous trading day?
The percentage price change of CYTOKINETICS INC (CYTK:NASDAQ) since the previous trading day is -0.5054%.
What is the most recent average sentiment score for CYTOKINETICS INC (CYTK:NASDAQ)?
The most recent average sentiment score for CYTOKINETICS INC (CYTK:NASDAQ) is 67 out of 100.
What is the most recent average sentiment for CYTOKINETICS INC (CYTK:NASDAQ)?
The most recent sentiment for CYTOKINETICS INC (CYTK:NASDAQ) is .
SEC-8K** Filing Available For CYTOKINETICS INC (CYTK:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.